In a patient with active influenza infection scheduled for elective coronary artery bypass grafting (CABG), should the surgery be delayed and what antiviral therapy is recommended before proceeding?

Elective CABG Should Be Delayed in Patients with Active Influenza, with Antiviral Treatment Initiated Immediately

In patients with active influenza infection scheduled for elective CABG, surgery must be delayed and antiviral therapy with oseltamivir or baloxavir should be initiated immediately, with surgery postponed until viral clearance is documented or at minimum 14 days after symptom onset.

Surgical Timing and Risk Assessment

The most recent and highest-quality evidence demonstrates that influenza within 14 days preoperatively significantly increases postoperative complications 1. Specifically, patients with influenza within 1-7 days before surgery face:

• 2.22-fold increased risk of postoperative pneumonia
• 1.98-fold increased risk of septicemia
• 2.10-fold increased risk of acute renal failure
• Increased ICU admission rates and prolonged hospital stays

The risk remains elevated but diminishes between days 8-14, suggesting a minimum 14-day delay is prudent for elective procedures 1.

Critical Timing Considerations

• Highest risk period: Days 1-7 after influenza symptom onset
• Moderate risk period: Days 8-14 after symptom onset
• Recommended delay: Minimum 14 days, ideally until viral clearance confirmed by PCR

Antiviral Therapy Protocol

For Severe or High-Risk Patients (CABG candidates qualify as high-risk due to planned major surgery):

Oseltamivir remains the primary recommendation 2, 3:

• Dose: 75 mg twice daily
• Renal adjustment: 75 mg once daily if CrCl <30 mL/min 4
• Duration: Continue beyond standard 5 days until viral clearance documented by PCR 4
• Timing: Initiate immediately, even if >48 hours from symptom onset (unlike healthy individuals, high-risk patients benefit regardless of symptom duration) 4

Alternative: Baloxavir 2, 3:

• Conditionally recommended for high-risk non-severe cases
• Must be initiated within 2 days of symptom onset
• Single-dose regimen may improve compliance

Important Caveats for Cardiac Surgery Patients:

• Do NOT use live attenuated intranasal vaccine - only inactivated vaccine is appropriate for cardiovascular disease patients 5
• Consider doubling oseltamivir dose to 150 mg twice daily in critically ill patients 4
• Monitor for prolonged viral shedding, which is common in immunocompromised states (relevant given perioperative stress and potential steroid use) 4

Verification of Viral Clearance

Before proceeding with surgery:

1. Obtain RT-PCR or NAAT testing - most sensitive and specific 2, 6
2. Repeat testing weekly until negative 4
3. Do NOT rely on rapid antigen tests alone - sensitivity ranges only 10-51% 4
4. Continue antiviral therapy until PCR negativity confirmed 4

Perioperative Infection Prevention

Once surgery proceeds after viral clearance, implement comprehensive pulmonary infection prevention strategies 7:

• Preoperative respiratory optimization and prehabilitation
• Intraoperative lung-protective ventilation strategies
• Postoperative early mobilization and respiratory exercises

Common Pitfalls to Avoid

1. Do NOT proceed with elective CABG during active infection - the 2-fold increase in septicemia and pneumonia risk is unacceptable for elective surgery 1

2. Do NOT stop antivirals at 5 days - immunocompromised and high-risk patients require extended therapy until viral clearance 4

3. Do NOT use rapid antigen tests as sole diagnostic - negative results cannot exclude influenza; use RT-PCR/NAAT 4, 6

4. Do NOT withhold antivirals if >48 hours from symptom onset - high-risk patients benefit regardless of timing 4

5. Do NOT use amantadine or rimantadine - current influenza strains are resistant 4

Resistance Monitoring

If viral replication persists beyond 7-10 days despite therapy 4:

• Suspect antiviral resistance (particularly H275Y mutation for oseltamivir)
• Consider switching to zanamivir (typically remains effective against oseltamivir-resistant strains)
• Obtain resistance testing if available

Risk-Benefit Analysis

While delaying elective CABG carries its own risks (progression of coronary disease, acute coronary events), the documented 2-fold increase in life-threatening postoperative complications during active influenza infection makes delay mandatory 1. The cardiovascular benefits of influenza vaccination in this population further underscore the serious interaction between influenza and cardiovascular disease 5.